Volume | 6,082,773 |
|
|||||
News | - | ||||||
Day High | 1.68 | Low High |
|||||
Day Low | 1.42 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sunshine Biopharma Inc | SBFM | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.67 | 1.42 | 1.68 | 1.44 | 1.765 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
28,268 | 6,082,773 | $ 1.57 | $ 9,551,087 | - | 1.42 - 140.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:52 | formt | 150 | $ 1.42 | USD |
Sunshine Biopharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
36.98M | 25.68M | - | 24.09M | -4.51M | -0.18 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sunshine Biopharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SBFM Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 7.60 | 8.30 | 1.42 | 5.56 | 15,148,736 | -6.18 | -81.32% |
1 Month | 6.20 | 13.25 | 1.42 | 9.35 | 29,272,776 | -4.78 | -77.10% |
3 Months | 24.00 | 28.56 | 1.42 | 8.34 | 25,881,994 | -22.58 | -94.08% |
6 Months | 31.00 | 32.98 | 1.42 | 8.46 | 12,188,780 | -29.58 | -95.42% |
1 Year | 70.00 | 140.00 | 1.42 | 12.79 | 6,434,638 | -68.58 | -97.97% |
3 Years | 275.00 | 987.00 | 1.42 | 176.05 | 4,490,891 | -273.58 | -99.48% |
5 Years | 275.00 | 987.00 | 1.42 | 176.05 | 4,490,891 | -273.58 | -99.48% |
Sunshine Biopharma Description
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). |